Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Academic CD19 CAR-T for R/R B-ALL and B-NHL
NCT06101381Phase 2Recruiting
- Sponsor
- Universidade de São Paulo
- Start
- Mar 2024
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of anti-CD19 CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL), B-cell non-Hodgkin lymphoma, sponsored by Universidade de São Paulo. Started Mar 2024; status: recruiting.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06101381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06101381.